The first patient has been treated with a cell-based therapy for the treatment of ischemic HF as a part of a pivotal phase 3 trial, according to a press release from Johns Hopkins Medicine, the Maryland Stem Cell Research Fund and BioCardia Inc.
The therapy (CardiAMP, BioCardia Inc.) involves the delivery of a high dose of a patient’s own bone marrow cells into the areas of cardiac dysfunction. According to the release, this could stimulate the body’s natural healing mechanism after MI.
The CardiAMP trial is a phase 3, multicenter, randomized, double blind study of up to 260 patients with NYHA Class II or III HF as a result of previous MI. The primary endpoint in the trial is improvement in 6-minute walk distance at 12 months after treatment.